Precigen to Launch Papziemos After Early Approval, Shares Up 89.8%
FDA granted early approval to Papziemos, the first off-the-shelf immunotherapy for recurrent respiratory papillomatosis, enabling Precigen to launch and self-fund its pipeline. Shares have gained 89.84% over the past 52 weeks, boosting capitalization to $1.256 billion and earning recognition as a top contributor in Patient Opportunity Equity Strategy's Q4 letter.
1. Early Approval of Papziemos
The FDA granted early approval to Papziemos for recurrent respiratory papillomatosis, making it the first off-the-shelf immunotherapy for a patient population with no prior treatment options. This milestone enables Precigen to address an unmet medical need and generate initial commercial revenues.
2. Launch Strategy and Pipeline Funding
Precigen plans to rapidly launch Papziemos, using drug sales to self-fund development of additional gene and cell therapy candidates in immuno-oncology, autoimmune disorders, and infectious diseases. Leadership under Dr. Helen Sabzevari drives clinical advancement across the pipeline.
3. Recent Stock Performance
Precigen shares have gained 89.84% over the past 52 weeks despite a 16.27% one-month decline, reflecting market volatility around the drug launch. The company's market capitalization stands at $1.256 billion as of March 4, 2026.
4. Investor Recognition
Patient Opportunity Equity Strategy highlighted Precigen as a top contributor in its Q4 2025 letter, attributing outperformance to the early Papziemos approval and portfolio selection. This endorsement underlines growing institutional interest in the company’s growth prospects.